OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture

New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP manufacturing by up to nine months, driven by key innovations and efficiencies across upstream and downstream processes Oxford, UK - 13 April 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the launch of its new fast-track development and manufacturing offering, providing an expedited route to GMP manufacture for clients utilising lentiviral (LV) and adeno-associated viral (AAV) vectors.